Effect of gonadotrophin-releasing hormone agonist treatment on growth hormone secretion in women with polycystic ovarian syndrome

By Kaltsas T  

Human Reproduction, Vol. 13, Iss. 1, 1998-01 ,pp. : 22-26

Oxford University Press

Access to resources Recommend Favorite

Gonadotrophin-releasing hormone-antagonists vs long agonist in in-vitro fertilization patients with polycystic ovary syndrome: a meta-analysis

By Mancini Fulvia   Tur Rosa   Martinez Francisca   Coroleu Buenaventura   Rodrííguez Ignacio   Barri Pedro N.  

Gynecological Endocrinology, Vol. 27, Iss. 3, 2011-03 ,pp. : 150-155

Informa Healthcare

Access to resources Recommend Favorite

17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation.

By Sahin Y   Keleştimur F  

Human Reproduction, Vol. 12, Iss. 5, 1997-05 ,pp. : 910-913

Oxford University Press

Access to resources Recommend Favorite

Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence

By Lee Dong-Yun   Bae Duk-Soo   Yoon Byung-Koo   Choi DooSeok  

Human Reproduction, Vol. 25, Iss. 12, 2010-12 ,pp. : 3050-3054

Oxford University Press

Access to resources Recommend Favorite

Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles

By Peñarrubia J  

Human Reproduction, Vol. 13, Iss. 12, 1998-12 ,pp. : 3315-3318

Oxford University Press

Access to resources Recommend Favorite